Brokerages predict that CryoPort Inc (NASDAQ:CYRX) will announce $7.82 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for CryoPort’s earnings, with the lowest sales estimate coming in at $7.40 million and the highest estimate coming in at $8.10 million. CryoPort reported sales of $4.63 million during the same quarter last year, which indicates a positive year over year growth rate of 68.9%. The firm is expected to report its next earnings report on Thursday, August 8th.
On average, analysts expect that CryoPort will report full-year sales of $33.76 million for the current fiscal year, with estimates ranging from $32.00 million to $35.69 million. For the next year, analysts expect that the business will report sales of $51.44 million, with estimates ranging from $47.00 million to $58.53 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that cover CryoPort.
CryoPort (NASDAQ:CYRX) last released its quarterly earnings data on Thursday, May 2nd. The consumer goods maker reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). The company had revenue of $6.65 million during the quarter, compared to the consensus estimate of $6.56 million. CryoPort had a negative return on equity of 28.30% and a negative net margin of 41.61%. The firm’s revenue for the quarter was up 65.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.10) EPS.
In related news, Director Richard J. Berman sold 30,000 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $11.84, for a total value of $355,200.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 11.00% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of CYRX. JPMorgan Chase & Co. increased its position in CryoPort by 35.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 216,523 shares of the consumer goods maker’s stock worth $2,774,000 after buying an additional 57,154 shares during the period. MetLife Investment Advisors LLC boosted its position in CryoPort by 55.2% in the third quarter. MetLife Investment Advisors LLC now owns 18,910 shares of the consumer goods maker’s stock worth $242,000 after purchasing an additional 6,722 shares during the last quarter. Teachers Advisors LLC lifted its position in shares of CryoPort by 10.4% during the 3rd quarter. Teachers Advisors LLC now owns 53,085 shares of the consumer goods maker’s stock valued at $680,000 after buying an additional 5,002 shares during the last quarter. Rhumbline Advisers lifted its position in shares of CryoPort by 50.1% during the 4th quarter. Rhumbline Advisers now owns 33,919 shares of the consumer goods maker’s stock valued at $374,000 after buying an additional 11,321 shares during the last quarter. Finally, Creative Planning lifted its position in shares of CryoPort by 3.9% during the 4th quarter. Creative Planning now owns 610,019 shares of the consumer goods maker’s stock valued at $6,729,000 after buying an additional 22,679 shares during the last quarter. Hedge funds and other institutional investors own 52.87% of the company’s stock.
Shares of NASDAQ CYRX traded up $0.34 during trading hours on Tuesday, hitting $17.38. The company had a trading volume of 150,609 shares, compared to its average volume of 213,129. The company has a market cap of $533.15 million, a PE ratio of -56.06 and a beta of 1.10. The company has a current ratio of 11.57, a quick ratio of 11.52 and a debt-to-equity ratio of 0.42. CryoPort has a 1-year low of $8.28 and a 1-year high of $18.11.
CryoPort Company Profile
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
Featured Article: Why is the ex-dividend date different from the record date?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.